{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-091225","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.858980+00:00","generated_at":"2026-06-23T23:56:44.030226+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acurx reports Q2 2022 net loss of $2.6M; Phase 2b trial enrollment continues with site expansion","bullets":["Net loss $2.6M ($0.26/diluted) for Q2 2022 vs $4.0M ($0.57) a year ago.","Cash $9.1M at June 30, 2022, down from $13.1M at Dec 31, 2021.","Phase 2b CDI trial enrollment slower; up to 30 clinical sites being added.","Raised $4.225M via July 2022 direct offering to institutional investor and executives.","Ibezapolstat showed favorable killing kinetics vs vancomycin in lab studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-091225","json":"https://secwatch.observer/filing/0001104659-22-091225.json","markdown":"https://secwatch.observer/filing/0001104659-22-091225.md","text":"https://secwatch.observer/filing/0001104659-22-091225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465922091225/0001104659-22-091225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465922091225/tm2223469d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:56:44.030226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}